- Read Time: 4 mins
IMMUNAID, The European project willing to identify biomarkers for the diagnosis of rare systemic autoinflammatory diseases, has just opened clinical sites in Belgium, Switzerland and in the UK, reaching more than half of the full recruitment capacity.
The NLRP3 inflammasome is the most thoroughly studied of the inflammasomes, and represents a valuable target in the clinical evaluation and treatment of systemic autoinflammatory diseases (SAIDs). We’ve summarised the rapidly progressing field of NLRP3 inflammasome regulation and its wider implications, both in the laboratory and in the clinic.
Now the number of COVID-19 patients has reduced significantly, the hospitals can again focus on their core activities. Already activated sites are able to recruit patients again and new sites are being opened.
An intriguing elevated number of Kawasaki disease cases, a rare inflammatory disorder, are recently noticed. The current pandemic context clearly questions a possible link between the SARS-CoV-2 virus, and the Kawasaki disease phenotype.
The concept of autoinflammatory disorders was introduced by Daniel Kastner in 1999 (Michael McDermott was 1st author). Since then, characterization of these conditions has been continuously refined. After 20 years, McDermott, Caseley and Savic have advocated for a systems-based classification of the systemic autoinflammatory diseases (SAIDs) which defines the complex interplay of molecular mechanisms, and systems, at the heart of many monogenic and polygenic conditions.
Page 1 of 2